Junfeng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Junfeng Wang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Zhenpeng Guan
Orthopedics Department, Peking University Shougang Hospital, Beijing, China
5 shared publications - Keshi Zhang
Orthopedics Department, Orthopedics Department, Peking University Shougang Hospital, Beijing, Beijing, China
2 shared publications Zheng Pei
Orthopedics Department, Peking University Shougang Hospital, Beijing, China
2 shared publicationsBin Sun
Department of Orthopedics, Peking University International Hospital, Beijing, China
1 shared publication- Bin Yang
Department of Orthopedics, Peking University International Hospital, Beijing, China
1 shared publication - Chen Liu
Peking University International Hospital, Beijing, China
1 shared publication
Latest Publications
- 30 June 2026
- Published by SAGE Publications in Journal of Back and Musculoskeletal Rehabilitation
- Vol. 39 (6) , 2180-2188
Variability and influencing factors of posterior condylar offset in posterior-stabilized total knee arthroplasty
Background: Posterior condylar offset (PCO) is a crucial knee anatomic parameter closely linked with joint function. Its restoration during posterior-stabilized total knee arthroplasty (TKA) draws wide research attention. Most studies focus on the impact of the PCO alterations on soft tissue balance and postoperative function, while relevant contributing factors remain poorly investigated. Objective: To explore PCO variation after posterior-stabilized TKA and analyze potential influencing factors contributing to such changes. Methods: From November 2020 to November 2021, 146 consecutive participants with a diagnosis of severe knee osteoarthritis were enrolled for this prospective study. All participants underwent primary posterior-stabilized TKA utilizing 3D-printed patient-specific instrumentation. Perioperative clinical variables and radiographic parameters were assessed, and the osteotomy thickness in the posterior femoral condyle was quantified during the TKA procedure. Results: A total of 134 participants (17 males and 117 females) were recruited in this prospective study, including 72 patients (53.7%) with changes of PCO after TKA < 3 mm in group 1, and 62 patients (46.3%) with changes of PCO after TKA ≥ 3 mm in group 2. The demographic characteristics, clinical scores, and radiographic measurements of the two groups were comparable before TKA. In general, postoperative PCO was considerably reduced compared with preoperative PCO (29.77 ± 3.52 mm vs. 27.67 ± 2.99 mm, p < 0.001). Postoperative PCO reduction was noted in 99 patients (73.9%). The correlation analysis indicated a relatively weak positive relationship between PCO variation and the osteotomy of posterior lateral femoral condyle ( r = 0.282, p = 0.004). Moreover, radiographic evaluation revealed that patients in group 1 had a smaller preoperative posterior tibial slope (PTS, p < 0.001) and a smaller PTS change ( p = 0.002) after TKA. Conclusion: PCO tends to decrease after posterior-stabilized TKA. The osteotomy in posterior lateral femoral condyle may potentially serve as a direct influencing factor for such reduction. The preoperative PTS and a greater PTS change were found to be indirect influencing factors associated with PCO variability in posterior-stabilized TKA. These imply that the anatomical morphology in posterior femoral condyle should not be sacrificed for the pursuit of uniform femoral and tibial osteotomy concepts.
- 30 June 2026
- Published by SAGE Publications in Journal of Back and Musculoskeletal Rehabilitation
- Vol. 39 (6) , 2180-2188
Variability and influencing factors of posterior condylar offset in posterior-stabilized total knee arthroplasty
Background: Posterior condylar offset (PCO) is a crucial knee anatomic parameter closely linked with joint function. Its restoration during posterior-stabilized total knee arthroplasty (TKA) draws wide research attention. Most studies focus on the impact of the PCO alterations on soft tissue balance and postoperative function, while relevant contributing factors remain poorly investigated. Objective: To explore PCO variation after posterior-stabilized TKA and analyze potential influencing factors contributing to such changes. Methods: From November 2020 to November 2021, 146 consecutive participants with a diagnosis of severe knee osteoarthritis were enrolled for this prospective study. All participants underwent primary posterior-stabilized TKA utilizing 3D-printed patient-specific instrumentation. Perioperative clinical variables and radiographic parameters were assessed, and the osteotomy thickness in the posterior femoral condyle was quantified during the TKA procedure. Results: A total of 134 participants (17 males and 117 females) were recruited in this prospective study, including 72 patients (53.7%) with changes of PCO after TKA < 3 mm in group 1, and 62 patients (46.3%) with changes of PCO after TKA ≥ 3 mm in group 2. The demographic characteristics, clinical scores, and radiographic measurements of the two groups were comparable before TKA. In general, postoperative PCO was considerably reduced compared with preoperative PCO (29.77 ± 3.52 mm vs. 27.67 ± 2.99 mm, p < 0.001). Postoperative PCO reduction was noted in 99 patients (73.9%). The correlation analysis indicated a relatively weak positive relationship between PCO variation and the osteotomy of posterior lateral femoral condyle ( r = 0.282, p = 0.004). Moreover, radiographic evaluation revealed that patients in group 1 had a smaller preoperative posterior tibial slope (PTS, p < 0.001) and a smaller PTS change ( p = 0.002) after TKA. Conclusion: PCO tends to decrease after posterior-stabilized TKA. The osteotomy in posterior lateral femoral condyle may potentially serve as a direct influencing factor for such reduction. The preoperative PTS and a greater PTS change were found to be indirect influencing factors associated with PCO variability in posterior-stabilized TKA. These imply that the anatomical morphology in posterior femoral condyle should not be sacrificed for the pursuit of uniform femoral and tibial osteotomy concepts.
- 27 October 2020
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 24 (1) , 90-95
Vaspin deficiency failed to promote the proliferation of BMSCs in osteoarthritis
Objective: The aim of this study was to estimate the possible role of vaspin in the proliferation of bone mesenchymal stem cells (BMSCs) and its molecular mechanisms in the bone marrow microenvironment of osteoarthritis (OA).Methods: This study included 15 non‐obese elderly patients with severe knee OA and 15 non‐obese controls with femoral neck fracture. Patients all underwent hip or knee arthroplasty surgery to restore joint shape and function. Bone marrow samples were taken during surgery to estimate vaspin and transforming growth factor (TGF)‐β1 levels by enzyme‐linked immunosorbent assay and to observe the effect of vaspin on BMSCs proliferation by Cell Counting Kit‐8. Real‐time polymerase chain reaction and western blot were performed to evaluate the effect of vaspin on the genes and proteins of Akt involved in the PI3K/AKT signaling pathway.Results: Bone marrow vaspin levels were significantly lower in OA patients compared to controls (P = .03). Furthermore, we found a significant correlation between vaspin and TGF‐β1 concentrations in bone marrow (r = .60, P < .01). In addition, the in vitro studies indicated the proliferation of BMSCs was significantly promoted when the vaspin treatment concentration was 150 ng/mL (P < .01). Meanwhile, we found that the Akt messenger RNA and pAkt protein levels in BMSCs were increased after vaspin treatment (P < .05).Conclusion: The findings of this study suggest there was abnormal expression of vaspin in OA bone marrow microenvironment, and vaspin likely had a mediator role in the proliferation of BMSCs, which may work by promoting the activation of the PI3K/AKT signaling pathway.
- 27 October 2020
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 24 (1) , 90-95
Vaspin deficiency failed to promote the proliferation of BMSCs in osteoarthritis
Objective: The aim of this study was to estimate the possible role of vaspin in the proliferation of bone mesenchymal stem cells (BMSCs) and its molecular mechanisms in the bone marrow microenvironment of osteoarthritis (OA).Methods: This study included 15 non‐obese elderly patients with severe knee OA and 15 non‐obese controls with femoral neck fracture. Patients all underwent hip or knee arthroplasty surgery to restore joint shape and function. Bone marrow samples were taken during surgery to estimate vaspin and transforming growth factor (TGF)‐β1 levels by enzyme‐linked immunosorbent assay and to observe the effect of vaspin on BMSCs proliferation by Cell Counting Kit‐8. Real‐time polymerase chain reaction and western blot were performed to evaluate the effect of vaspin on the genes and proteins of Akt involved in the PI3K/AKT signaling pathway.Results: Bone marrow vaspin levels were significantly lower in OA patients compared to controls (P = .03). Furthermore, we found a significant correlation between vaspin and TGF‐β1 concentrations in bone marrow (r = .60, P < .01). In addition, the in vitro studies indicated the proliferation of BMSCs was significantly promoted when the vaspin treatment concentration was 150 ng/mL (P < .01). Meanwhile, we found that the Akt messenger RNA and pAkt protein levels in BMSCs were increased after vaspin treatment (P < .05).Conclusion: The findings of this study suggest there was abnormal expression of vaspin in OA bone marrow microenvironment, and vaspin likely had a mediator role in the proliferation of BMSCs, which may work by promoting the activation of the PI3K/AKT signaling pathway.
- 1 January 2020
- Published by Wolters Kluwer Health in JBJS Case Connector
- Vol. 10 (3) , e20.00068
Hemophagocytic Syndrome Caused by Methotrexate Overdose in a Total Knee Arthroplasty Patient
Case: We report a patient with rheumatoid arthritis (RA) who developed hemophagocytic syndrome (HPS). The HPS was attributed to sepsis, itself a consequence of methotrexate (MTX) overdose. The discovery of MTX overdose was facilitated by the presence of epidermolysis bullosa, multiple ulcers of the whole digestive tract, and additional history from the patient's family. Conclusion: For arthroplasty patients with underlying inflammatory disorders such as RA, drug history should be thoroughly inquired. Correct diagnosis results from careful history review, detailed physical examination, and necessary laboratory tests.
- 1 January 2020
- Published by Wolters Kluwer Health in JBJS Case Connector
- Vol. 10 (3) , e20.00068
Hemophagocytic Syndrome Caused by Methotrexate Overdose in a Total Knee Arthroplasty Patient
Case: We report a patient with rheumatoid arthritis (RA) who developed hemophagocytic syndrome (HPS). The HPS was attributed to sepsis, itself a consequence of methotrexate (MTX) overdose. The discovery of MTX overdose was facilitated by the presence of epidermolysis bullosa, multiple ulcers of the whole digestive tract, and additional history from the patient's family. Conclusion: For arthroplasty patients with underlying inflammatory disorders such as RA, drug history should be thoroughly inquired. Correct diagnosis results from careful history review, detailed physical examination, and necessary laboratory tests.
- Open Access
- 8 July 2019
- Published by Wiley in Orthopaedic Surgery
- Vol. 11 (4) , 698-704
Effects of Tumor Necrosis Factor Alpha on the Expression of Programmed Cell Death Factor 5 in Arthritis
Objective: To investigate the effect of tumor necrosis factor alpha (TNF‐α) on the proliferation of fibroblast‐like synoviocytes (FLS) and the expression of programmed cell death factor 5 (PDCD5) in an inflammatory microenvironment, for the further understanding of the mechanism of action of TNF‐α in promoting the proliferation of synovial cells and the apoptosis of the chondrocytes.Methods: Articular carriage specimens were obtained from 21 cases with osteoarthritis and 12 cases with femoral neck fractures as healthy controls during arthroplasties. The expression of PDCD5 was evaluated by immunofluorescence analyzed by mean option density (MOD) detected using the software ImagePro Plus. Real‐time PCR was performed to evaluate the transcriptions of PDCD5 and TNF‐α in synovium. FLS cells derived from rheumatoid arthritis patients were cultured in vitro and incubated with different concentrations of TNF‐α. The effects of TNF‐α at different concentrations on the proliferation of FLS cells were detected by Cell Counting Kit‐8 (CCK‐8) assay to evaluate the cell proliferation rate. After incubation with the absence or presence of recombinant human TNF‐α at different concentrations, the FLS cells were isolated for detection of PDCD5 protein and PDCD5 gene. The expression of PDCD5 protein was detected by western‐blot and the transcription of PDCD5 gene from the cells was detected by real‐time quantitative PCR.Results: The MOD of PDCD5 as well as TNF‐α of osteoarthritis cartilage sections were significantly increased compared with those of the controls, and in synovium there was a positive correlation between transcriptions of their mRNA. When the concentration of TNF‐α was 1 ng/mL, the cell proliferation rate was not significantly different from that of the control group (P = 0.592), while the proliferation of FLS cells was significantly promoted when the concentration of TNF‐α was 5, 10, 15, or 20 ng/mL, and the proliferation‐promoting rates were 35.64% ± 6.96%, 48.72% ± 7.69%, 45.60% ± 8.85%, and 39.32% ± 6.18%, respectively (P < 0.01). The transcription of PDCD5 gene was significantly downregulated, which was 80.44% ± 4.07% and 84.30% ± 5.48%, respectively (P < 0.05), in the FLS cells incubated with TNF‐α at the concentration of 10 and 15 ng/mL for 24 h. When the concentration of TNF‐α was 1, 5, or 20 ng/mL, the transcription of PDCD5 mRNA in FLS cells was not significantly different from that in the control group (P > 0.05). The expression of PDCD5 protein was only significantly downregulated when the concentration of TNF‐α was 10 ng/mL (P < 0.01), while the expression of PDCD5 protein in FLS cells was not significantly different from that in the control group (P > 0.05).Conclusion: The expression of PDCD5 as well as TNF‐α in osteoarthritis cartilage and synovium was significantly higher than in healthy tissues, and TNF‐α can promote the proliferation of FLS cells in patients with rheumatoid arthritis, and inhibit the expression of PDCD5. PDCD5 may be involved in the abnormal proliferation of synoviocytes and the degeneration of chondrocytes stimulated by TNF‐α.
- 8 July 2019
- Published by Wiley in Orthopaedic Surgery
- Vol. 11 (4) , 698-704
Open AccessEffects of Tumor Necrosis Factor Alpha on the Expression of Programmed Cell Death Factor 5 in Arthritis
Objective: To investigate the effect of tumor necrosis factor alpha (TNF‐α) on the proliferation of fibroblast‐like synoviocytes (FLS) and the expression of programmed cell death factor 5 (PDCD5) in an inflammatory microenvironment, for the further understanding of the mechanism of action of TNF‐α in promoting the proliferation of synovial cells and the apoptosis of the chondrocytes.Methods: Articular carriage specimens were obtained from 21 cases with osteoarthritis and 12 cases with femoral neck fractures as healthy controls during arthroplasties. The expression of PDCD5 was evaluated by immunofluorescence analyzed by mean option density (MOD) detected using the software ImagePro Plus. Real‐time PCR was performed to evaluate the transcriptions of PDCD5 and TNF‐α in synovium. FLS cells derived from rheumatoid arthritis patients were cultured in vitro and incubated with different concentrations of TNF‐α. The effects of TNF‐α at different concentrations on the proliferation of FLS cells were detected by Cell Counting Kit‐8 (CCK‐8) assay to evaluate the cell proliferation rate. After incubation with the absence or presence of recombinant human TNF‐α at different concentrations, the FLS cells were isolated for detection of PDCD5 protein and PDCD5 gene. The expression of PDCD5 protein was detected by western‐blot and the transcription of PDCD5 gene from the cells was detected by real‐time quantitative PCR.Results: The MOD of PDCD5 as well as TNF‐α of osteoarthritis cartilage sections were significantly increased compared with those of the controls, and in synovium there was a positive correlation between transcriptions of their mRNA. When the concentration of TNF‐α was 1 ng/mL, the cell proliferation rate was not significantly different from that of the control group (P = 0.592), while the proliferation of FLS cells was significantly promoted when the concentration of TNF‐α was 5, 10, 15, or 20 ng/mL, and the proliferation‐promoting rates were 35.64% ± 6.96%, 48.72% ± 7.69%, 45.60% ± 8.85%, and 39.32% ± 6.18%, respectively (P < 0.01). The transcription of PDCD5 gene was significantly downregulated, which was 80.44% ± 4.07% and 84.30% ± 5.48%, respectively (P < 0.05), in the FLS cells incubated with TNF‐α at the concentration of 10 and 15 ng/mL for 24 h. When the concentration of TNF‐α was 1, 5, or 20 ng/mL, the transcription of PDCD5 mRNA in FLS cells was not significantly different from that in the control group (P > 0.05). The expression of PDCD5 protein was only significantly downregulated when the concentration of TNF‐α was 10 ng/mL (P < 0.01), while the expression of PDCD5 protein in FLS cells was not significantly different from that in the control group (P > 0.05).Conclusion: The expression of PDCD5 as well as TNF‐α in osteoarthritis cartilage and synovium was significantly higher than in healthy tissues, and TNF‐α can promote the proliferation of FLS cells in patients with rheumatoid arthritis, and inhibit the expression of PDCD5. PDCD5 may be involved in the abnormal proliferation of synoviocytes and the degeneration of chondrocytes stimulated by TNF‐α.
- Open Access
- 11 December 2017
- Published by Springer Nature in Biological Research
- Vol. 50 (1) , 40
Programmed cell death 5 transgenic mice attenuates adjuvant induced arthritis by 2 modifying the T lymphocytes balance
Programmed cell death 5 (PDCD5) is an apoptosis-related gene cloned from TF-1 cells whose primary biological functions are to promote apoptosis and immune regulation. The effects and mechanisms exerted by key mediators of arthritic inflammation remain unclear in PDCD5 transgenic (PDCD5 tg) mice. In the current study, PDCD5 tg mice inhibited the progression of adjuvant-induced arthritis, specifically decreasing clinical signs and histological damage, compared with arthritis control mice. Additionally, the ratio of CD4+IFN-γ+ cells (Th1) and CD4+IL-17A+ cells (Th17), as well as the mRNA expression of the pro-inflammatory mediators IFN-γ, IL-6, IL-17A and TNF-α, were decreased in PDCD5 tg mice, while CD4+CD25+Foxp3+ regulatory T (Treg) cells and the anti-inflammatory mediators IL-4 and IL-10 were increased. Furthermore, PDCD5 tg mice demonstrated reduced serum levels of IFN-γ, IL-6, IL-17A and TNF-α and increased levels of IL-4. Based on our data, PDCD5 exerts anti-inflammatory effects by modifying the T lymphocytes balance, inhibiting the production of pro-inflammatory mediators and promoting the secretion of anti-inflammatory cytokines, validating PDCD5 protein as a possible treatment for RA.
- 11 December 2017
- Published by Springer Nature in Biological Research
- Vol. 50 (1) , 40
Open AccessProgrammed cell death 5 transgenic mice attenuates adjuvant induced arthritis by 2 modifying the T lymphocytes balance
Programmed cell death 5 (PDCD5) is an apoptosis-related gene cloned from TF-1 cells whose primary biological functions are to promote apoptosis and immune regulation. The effects and mechanisms exerted by key mediators of arthritic inflammation remain unclear in PDCD5 transgenic (PDCD5 tg) mice. In the current study, PDCD5 tg mice inhibited the progression of adjuvant-induced arthritis, specifically decreasing clinical signs and histological damage, compared with arthritis control mice. Additionally, the ratio of CD4+IFN-γ+ cells (Th1) and CD4+IL-17A+ cells (Th17), as well as the mRNA expression of the pro-inflammatory mediators IFN-γ, IL-6, IL-17A and TNF-α, were decreased in PDCD5 tg mice, while CD4+CD25+Foxp3+ regulatory T (Treg) cells and the anti-inflammatory mediators IL-4 and IL-10 were increased. Furthermore, PDCD5 tg mice demonstrated reduced serum levels of IFN-γ, IL-6, IL-17A and TNF-α and increased levels of IL-4. Based on our data, PDCD5 exerts anti-inflammatory effects by modifying the T lymphocytes balance, inhibiting the production of pro-inflammatory mediators and promoting the secretion of anti-inflammatory cytokines, validating PDCD5 protein as a possible treatment for RA.
- 20 January 2013
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 126 (2) , 296-299
Programmed cell death 5 correlates with disease activity and interleukin-17 in serum and synovial fluid of rheumatoid arthritis patients
Background: Programmed cell death 5 (PDCD5) is a novel apoptotic regulatory gene that promotes apoptosis in various tumor cells. Studies have shown that PDCD5 accelerates the apoptosis of synoviocytes in vitro, implying a potential role in rheumatoid arthritis (RA) pathogenesis. This study examined the expression of PDCD5 in serum and synovial fluid of RA patients, its effect on the expression of inflammatory cytokine, interleukin-17 (IL-17), and the assessment of disease activity in RA. Methods: PDCD5 and IL-17 levels in serum and synovial fluid from 18 patients with RA and 22 patients with osteoarthritis (OA) were detected using enzyme-linked immunosorbent assay (ELISA). Concentrations of serum PDCD5 in 40 healthy people were also detected as controls. As disease activity indices, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), and X-ray grading scale were also evaluated. Results: Serum and synovial fluid PDCD5 levels in RA patients were significantly higher than those in OA and healthy controls. Serum PDCD5 level was inversely correlated to CRP and ESR, and was significantly higher in the RF negative group than in the positive group. PDCD5 level was also negatively correlated with IL-17 levels both in serum and synovial fluid of RA patients. However, differences in synovial fluid PDCD5 level from RA patients at different Larsen stages were not detectable. Conclusions: PDCD5 affects RA pathogenesis. Insufficient apoptosis of fibroblast-like synoviocytes and inflammatory cells in RA could increase the expression of PDCD5 protein. As PDCD5 levels correlated negatively with disease activity indices and IL-17 level, PDCD5 could become a target in the diagnosis and treatment of RA.
- 20 January 2013
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 126 (2) , 296-299
Programmed cell death 5 correlates with disease activity and interleukin-17 in serum and synovial fluid of rheumatoid arthritis patients
Background: Programmed cell death 5 (PDCD5) is a novel apoptotic regulatory gene that promotes apoptosis in various tumor cells. Studies have shown that PDCD5 accelerates the apoptosis of synoviocytes in vitro, implying a potential role in rheumatoid arthritis (RA) pathogenesis. This study examined the expression of PDCD5 in serum and synovial fluid of RA patients, its effect on the expression of inflammatory cytokine, interleukin-17 (IL-17), and the assessment of disease activity in RA. Methods: PDCD5 and IL-17 levels in serum and synovial fluid from 18 patients with RA and 22 patients with osteoarthritis (OA) were detected using enzyme-linked immunosorbent assay (ELISA). Concentrations of serum PDCD5 in 40 healthy people were also detected as controls. As disease activity indices, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), and X-ray grading scale were also evaluated. Results: Serum and synovial fluid PDCD5 levels in RA patients were significantly higher than those in OA and healthy controls. Serum PDCD5 level was inversely correlated to CRP and ESR, and was significantly higher in the RF negative group than in the positive group. PDCD5 level was also negatively correlated with IL-17 levels both in serum and synovial fluid of RA patients. However, differences in synovial fluid PDCD5 level from RA patients at different Larsen stages were not detectable. Conclusions: PDCD5 affects RA pathogenesis. Insufficient apoptosis of fibroblast-like synoviocytes and inflammatory cells in RA could increase the expression of PDCD5 protein. As PDCD5 levels correlated negatively with disease activity indices and IL-17 level, PDCD5 could become a target in the diagnosis and treatment of RA.
- 18 January 2013
- Published by Taylor & Francis in Biomarkers
- Vol. 18 (2) , 155-159
Plasma and synovial fluid programmed cell death 5 (PDCD5) levels are inversely associated with TNF-α and disease activity in patients with rheumatoid arthritis
Context: Programmed cell death 5 (PDCD5), a novel apoptotic regulatory gene, has been reported to be associated with rheumatoid arthritis (RA) and osteoarthritis (OA), which can regulate the apoptosis of synoviocytes and chondrocytes cultured in vitro. Objective: To study expression characteristic of PDCD5 in plasma and synovial fluid of RA patients, and analyze its correlation with tumor necrosis factor alpha (TNF-α) and disease activity in RA. Methods: A total of 135 subjects were recruited into this study (44 RA patients, 46 OA patients and 45 healthy controls). PDCD5 and TNF-α concentrations in plasma and synovial fluid were analyzed by enzyme-linked immunosorbent assay. Results: Plasma and synovial fluid PDCD5 concentrations were significantly elevated in RA patients. Pearson correlation analysis indicated that plasma and synovial fluid PDCD5 levels were inversely correlated with TNF-α. Moreover, plasma PDCD5 levels were also inversely correlated with C-reactive protein and erythrocyte sedimentation rate. Conclusion: Plasma and synovial fluid PDCD5 could be useful for monitoring the activity and progression of RA, and its abnormal expression and dysfunction may be correlated to TNF-α in RA patients.
- 18 January 2013
- Published by Taylor & Francis in Biomarkers
- Vol. 18 (2) , 155-159
Plasma and synovial fluid programmed cell death 5 (PDCD5) levels are inversely associated with TNF-α and disease activity in patients with rheumatoid arthritis
Context: Programmed cell death 5 (PDCD5), a novel apoptotic regulatory gene, has been reported to be associated with rheumatoid arthritis (RA) and osteoarthritis (OA), which can regulate the apoptosis of synoviocytes and chondrocytes cultured in vitro. Objective: To study expression characteristic of PDCD5 in plasma and synovial fluid of RA patients, and analyze its correlation with tumor necrosis factor alpha (TNF-α) and disease activity in RA. Methods: A total of 135 subjects were recruited into this study (44 RA patients, 46 OA patients and 45 healthy controls). PDCD5 and TNF-α concentrations in plasma and synovial fluid were analyzed by enzyme-linked immunosorbent assay. Results: Plasma and synovial fluid PDCD5 concentrations were significantly elevated in RA patients. Pearson correlation analysis indicated that plasma and synovial fluid PDCD5 levels were inversely correlated with TNF-α. Moreover, plasma PDCD5 levels were also inversely correlated with C-reactive protein and erythrocyte sedimentation rate. Conclusion: Plasma and synovial fluid PDCD5 could be useful for monitoring the activity and progression of RA, and its abnormal expression and dysfunction may be correlated to TNF-α in RA patients.